Professor Thomas Jaki and the city of Wuhan, China
A Lancaster University statistician who worked on the first published large randomised clinical trial for a potential treatment for the COVID-19 virus said the scientific community was coming together to combat the coronavirus.
There are currently no specific treatments for COVID-19. However, it is possible that some existing drugs, usually used for other conditions, may have some benefits.
The results were quite encouraging, which has led to further studies taking place and I would expect to see these treatments to be introduced into routine care, in some cases, in the coming weeks.
Professor Thomas Jaki, from the Medical and Pharmaceutical Statistics Research Unit in the Department of Mathematics and Statistics at Lancaster University, said the initial trial in Wuhan, China, investigated whether anti-viral drugs used to treat HIV would relieve the symptoms of COVID-19 – and started when there were less than 500 confirmed cases worldwide.
The trial saw 199 COVID-19 patients at Jin Yin-Tan Hospital treated either using standard of care or being given lopinavir–ritonavir. The results were published recently and showed enough promise that further, larger trials of the lopinavir–ritonavir treatment have now been established.
Specifically, the trial showed that patients who were randomly chosen to receive lopinavir–ritonavir appeared to improve faster. Meanwhile, among those patients who actually received lopinavir–ritonavir, the time to clinical improvement was significantly shorter than in patients receiving standard of care alone. At the same time acceptable safety levels were observed.
Professor Jaki said: “The results were quite encouraging, which has led to further studies taking place and I would expect to see these treatments to be introduced into routine care, in some cases, in the coming weeks.”
The findings from this study will also be considered as part of the forthcoming Randomised Evaluation of COVid-19 thERapY (RECOVERY) trial. This will provide a trial platform to evaluate some of the approximately 30 treatments which are currently believed to have potential for treatment of COVID-19. The chief investigator for that trial is Peter Horby, Professor of Emerging Infectious Diseases and Global Health in the Nuffield Department of Medicine at the University of Oxford – who was also part of the initial study in Wuhan.
Professor Jaki said the fact these studies were taking place during a medical emergency had seen a determination to move things forward at pace.
He added: “The astonishing thing about the RECOVERY trial is the speed with which it got off the ground, from the initial agreement being received from the Department of Health and Social Care it was just nine days before the first patient was recruited. That process would usually take between six and nine months.
“We have benefitted by learning from trials in China – keep it simple. RECOVERY uses a very short protocol and attempts to minimise burden on staff in hospitals which are overwhelmed, so we have tried to ensure data collection is simple. It is an important study and one which needs to be done quickly.
“This is one of the largest trials into treatments for COVID-19. There is a second large trial that is currently recruiting in the UK – REMAP-CAP – which is looking at impacts of treatments on severely ill patients, but both teams have worked together to ensure they will be able to learn as much as they can from both trials.
“This is unusual but a lot of the competitive nature of these things isn’t there at the moment. We all have the same goal.”
The RECOVERY trial has been classed as an Urgent Public Health Research Study. It is one of a round of projects to receive £10.5m as part of the £20m rapid research response funded by UK Research and Innovation, and by the Department of Health and Social Care through the National Institute for Health Research (NIHR).
Chief Medical Officer Professor Chris Whitty and NHS England Medical Director Professor Stephen Powis have written to NHS trusts in England asking them to fully support the new trial.
Professor Jaki is also one of the authors of an opinion piece published in the New England Medical Journal last week on an approach to clinical trials around large epidemics.
While the piece was predominantly written months before the coronavirus outbreak, it encourages greater collaboration between scientists and much of the advice is already being reflected in the World Health Organisation’s developing strategy.
Professor Jaki added: “This is the culmination of a conversation which started several years ago where the WHO recognised the necessity of pre-planning in the event of a disease outbreak.
“While it may sometimes feel like we are unprepared for incidents like the COVID-19 outbreak there is actually a co-ordinated global effort among scientists, and Lancaster plays its part in that.”
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
- Biden's case highlights coronavirus 'rebound,' experts say
A phenomenon known as coronavirus 'rebound' is in the spotlight after President Joe Biden tested positive for COVID-19 again Saturday morning following several days of testing negative.
- Patients testing positive for COVID-19 in New Hampshire hospitals remains steady over weekend
Patients testing positive for COVID-19 in New Hampshire hospitals remained fairly steady over the weekend, according to the New Hampshire Hospital Association.
- WA expands telehealth options to improve access to COVID treatment
Washington residents who test positive for the coronavirus can now get a free telehealth appointment for treatment consultation, regardless of their insurance coverage.
- Concerned about COVID-19?
It’s back to the White House balcony and the Treaty Room for President Joe Biden as he contends with a “rebound” case of COVID-19. Biden is trapped in the White ...
- Test & Treat? NYC Test & Trace Corps Get Rebrand for COVID Treatment Push
A program born out of the early days of the COVID-19 pandemic, back when infections made New York City the epicenter of the health crisis, is getting a facelift to meet the priorities of the city. The ...
Go deeper with Google Headlines on:
Go deeper with Bing News on:
- South Africa: SAHPRA Announces Approval of Breakthrough Treatments for Children with HIV
Press Release - SAHPRA has registered a new "sweet-tasting" combination antiretroviral treatment for infants and young children with HIV. This treatment comes in granules that can be sprinkled on soft ...
- South Africa: Experts Welcome New HIV Treatments for Kids
In a move widely welcomed by local experts, the South African Health Products Regulatory Authority (SAHPRA) recently approved new child-friendly formulations of several important antiretroviral ...
- Amid protests over HIV drugs ‘shortage’, govt says enough stock
The protesters, however, continue to sit outside the office of National AIDS Control Organisation, demanding that all the medicines be made available and sufficient stock be maintained so that pills ...
- Experts welcome new HIV drug formulations that cut out the ‘ew’ factor for children
New child-friendly formulations of several important antiretroviral medicines were recently approved by the South African Health Products Regulatory Authority. Thabo Molelekwa asks what this means for ...
- Cost Effectiveness of Lopinavir/Ritonavir Compared with Atazanavir plus Ritonavir in Antiretroviral-Experienced Patients in the US
Patients started with either lopinavir/ritonavir (LPV/r) or ritonavir-boosted atazanavir (ATV+RTV) as the protease inhibitor (PI). The proportions of patients with viral suppression below 400 and ...